Spinal Cord Injury D10 Level Before and After Stem Cell Treatment
Stem Cell Treatment done at Neurogen ,Brain Spine Institute, Surana Sethia Hospital and Research Centre, Suman Nagar, Sion-Trombay Road, Chembur,Mumbai-71. Website -- http://www.neurogen.in http://www.stemcellsmumbai.com Tel: - +91 9920 200400, 022-25283706From:neurogenbsiViews:7 1ratingsTime:01:23More inScience Technology

The rest is here:
Spinal Cord Injury D10 Level Before and After Stem Cell Treatment - Video

Recommendation and review posted by sam

The Neurobiology Of Painting: International Review Of Neurobiology
ll4.me The Neurobiology Of Painting: International Review Of Neurobiology The book presents a basis for the interaction of the brain and nervous system with painting, music and literature, and a discussion of art from multiple facets - such as anatomy, migraine, illusion and evolutionary biology. The book explores several aspects of the neurobiology of painting, including evolutionary neurobiology, sensation vs. perception, the visual brain and how the mind works, and also explores the affects of brain disorders and trauma on artist, with a concluding chapter on Frida Kahlo and the spinal cord injury that influenced her painting. Publisher: Academic Press Illustration: N Language: ENG Title: The Neurobiology of Painting: International Review of Neurobiology Pages: 00360 (Encrypted PDF) On Sale: 2006-04-03 SKU-13/ISBN: 9780123668752 Category: Medical : Neurology - General Category: Medical : Neuroscience The book presents a basis for the interaction of the brain and nervous system with painting, music and literature, and a discussion of art from multiple facets - such as anatomy, migraine, illusion an medical, neurology, general, neuroscienceFrom:kennethphillips214Views:0 0ratingsTime:00:12More inPeople Blogs

Read more here:
The Neurobiology Of Painting: International Review Of Neurobiology - Video

Recommendation and review posted by sam

JON FSWC
Jon B from Winnipeg spent a good amount of time with us being able to stand on his own for short periods of time, increasing his nervous system activity below his level of injury, and even pedaling a spin bike on his own. Jon was adamant in educating himself in proper nutrition and current spinal cord injury research, it was a common site to see Jon bringing his supplements to take pre- and post-workout.From:FSWCReginaViews:2 0ratingsTime:01:17More inScience Technology

More here:
JON FSWC - Video

Recommendation and review posted by sam

Sexual Health Part 2
information on sexual health after a spinal cord injuryFrom:cpaalbertaViews:3 0ratingsTime:09:39More inNonprofits Activism

More here:
Sexual Health Part 2 - Video

Recommendation and review posted by sam

Sexual Health after Spinal Cord Injury Part 1
information on sexual health after spinal cord injuryFrom:cpaalbertaViews:14 1ratingsTime:09:24More inNonprofits Activism

See original here:
Sexual Health after Spinal Cord Injury Part 1 - Video

Recommendation and review posted by sam

Robotics Institute and Center for Urology, Winter Haven, FL
We are one of the premier Urology Institutes to incorporate the daVinci Si High Definition Robotic Surgical System. The use of the daVinci Si with an additional instrument arm and high definition camera allows for improved surgical efficiency. We offer a full array of treatment options for male infertility: Robotic Vasectomy Reversal Robotic Vasosvasostomy Robotic Vasoepididymostomy Robotic TESE (Testicular Sperm Extraction) Robotic Varicocelectomy PESA (Percutaneous Epididymal Sperm Aspiration) MESA (Microsurgical Epididymal Sperm Extraction) Testis Biopsy Sperm Cryopreservation Electroejaculation - Spinal Cord Injury Vibratory Ejaculation - Spinal Cord Injury Complete Sperm Analysis Retrograde Ejaculation Treatment We have also developed a comprehensive multi-disciplinary clinic that specializes in the evaluation and treatment of chronic groin and/or testicular pain. This clinic incorporates elements of physical therapy, pain management and urology. The goal is to offer comprehensive patient care and deliver innovation treatment options for patients with chronic testicular and/or groin pain. We offer the following testicular / groin / inguinal pain procedures: Mapped groin inguinal spermatic cord blocks Targeted Robotic Microsurgical Neurolysis/Denervation of the spermatic cord Sub-inguinal abdominal approaches Botox Blocks Micro-Cryo Ablation of nerve fibers We strive to deliver world class care and our team is dedicated to providing you with information about male ...From:RICFUrologyViews:0 0ratingsTime:03:02More inScience Technology

Read the original post:
Robotics Institute and Center for Urology, Winter Haven, FL - Video

Recommendation and review posted by sam

HoustonPBS UH Moment: Brain-Controlled Exoskeleton Making Strides
Steve Holbert was paralyzed in a dirt bike accident in late 2009. His hope is to completely recover from his spinal cord injury and one day walk again. That #39;s why he #39;s agreed to participate in the research of Jose Luis "Pepe" Contreras-Vidal, professor of electrical and computer engineering at the University of Houston #39;s Cullen College of Engineering and director of the Laboratory for Non-invasive Brain-Machine Interface Systems. Contreras-Vidal is working on a brain-machine interface (BMI) that would allow patients like Holbert to control prosthetic limbs through their own thoughts.From:UHmultimediaViews:4 1ratingsTime:01:05More inScience Technology

Read more:
HoustonPBS UH Moment: Brain-Controlled Exoskeleton Making Strides - Video

Recommendation and review posted by sam

Speech 2- Spinal Cord Injury Treatments
From:trckc01Views:2 0ratingsTime:06:07More inPeople Blogs

Read more:
Speech 2- Spinal Cord Injury Treatments - Video

Recommendation and review posted by sam

Physical Therapy Gait and Harness system number 1
My Physical Therapy with using the harness system and parallel bars, Working with my physical therapist, DX Transverse myelitis , Incomplete Quadriplegic C5/6 Spinal cord injuryFrom:myQuadTherapyViews:0 0ratingsTime:01:29More inPeople Blogs

View post:
Physical Therapy Gait and Harness system number 1 - Video

Recommendation and review posted by sam

Physical Therapy Gait and Harness system number 2
My Physical Therapy with using the harness system and parallel bars, Working with my physical therapist, DX Transverse myelitis , Incomplete Quadriplegic C5/6 Spinal cord injuryFrom:myQuadTherapyViews:0 0ratingsTime:02:33More inPeople Blogs

Read the rest here:
Physical Therapy Gait and Harness system number 2 - Video

Recommendation and review posted by sam

ScienceDaily (Nov. 6, 2012) Scientists at the Universities of Liverpool and Glasgow have uncovered a possible new method of enhancing nerve repair in the treatment of spinal cord injuries.

It is known that scar tissue, which forms following spinal cord injury, creates an impenetrable barrier to nerve regeneration, leading to the irreversible paralysis associated with spinal injuries. Scientists at Liverpool and Glasgow have discovered that long-chain sugars, called heparan sulfates, play a significant role in the process of scar formation in cell models in the laboratory.

Research findings have the potential to contribute to new strategies for manipulating the scarring process induced in spinal cord injury and improving the effectiveness of cell transplantation therapies in patients with this type of injury.

Scarring occurs due to the activation, change in shape, and stiffness of cells, called astrocytes, which are the major nerve support cells in the spinal cord. One possible way to repair nerve damage is transplantation of support cells from peripheral nerves, called Schwann cells. The team, however, found that these cells secrete heparan sulfate sugars, which promote scarring reactions and could reduce the effectiveness of nerve repair.

Scientists showed that these sugars can over-activate protein growth factors that promote astrocyte scarring. Significantly, however, they found this over-activation could be inhibited by chemically modified heparins made in the laboratory. These compounds could prevent the scarring reaction of astrocyte cells, opening up new opportunities for treatment of damaged nerve cells.

Professor Jerry Turnbull, from the University of Liverpool's Institute of Integrative Biology, said: "Spinal injury is a devastating condition and can result in paralysis for life. The sugars we are investigating are produced by nearly every cell in the body, and are similar to the blood thinning drug heparin.

"We found that some sugar types promote scarring reaction, but remarkably other types, which can be chemically produced in the laboratory by modifying heparin, can prevent this in our cell models.

"Studies in animal cells are now needed, but the exciting thing about this work is that it could, in the future, provide a way of developing treatments for improving nerve repair in patients, using the body's own Schwann cells, supplemented with specific sugars."

Professor Sue Barnett, from the University of Glasgow's Institute of Infection, Immunity and Inflammation, said: "We had already shown that Schwann cells, identified as having the potential to promote nerve regrowth, induced scarring in spinal cord injury. Now that we know that they secrete these complex sugars, which lead to scarring, we have the opportunity to intervene in this process, and promote central nervous system repair."

The research, funded by the Wellcome Trust, is published in the Journal of Neuroscience.

See more here:
Discovery may help nerve regeneration in spinal injury

Recommendation and review posted by sam

CHARLOTTE, N.C., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (CHTP) today announced results from a study of Northera(TM) (droxidopa) in hypotensive individuals with spinal cord injury at the 23rd International Symposium on the Autonomic Nervous System, which took place October 31 through November 3, 2012 in Paradise Island, Bahamas.

The poster, titled "Blood Pressure Effect of Droxidopa in Hypotensive Individuals with Spinal Cord Injury," (poster #62) highlighted results of a clinical study designed to determine the blood pressure effect of escalating doses of droxidopa (100 mg, 200 mg & 400 mg) during three laboratory visits in hypotensive subjects (n=10) with spinal cord injury (SCI). The level of SCI ranged from cervical to low thoracic lesions, all were chronically injured and non-ambulatory and 8 were motor complete.

Subjects were hypotensive at baseline (systolic BP: 87+/-14 mmHg; diastolic BP: 54+/-8 mmHg), and baseline BP did not differ among the 3 visits. Upon supine repositioning prior to drug administration, BP increased significantly (SBP: 101+/-11 mmHg; DBP: 62+/-7 mmHg; p<0.0001 versus seated baseline), regardless of dose, droxidopa did not augment the increase in BP upon supine repositioning. Seated BP was significantly increased from baseline after droxidopa in a dose-dependent manner (100 mg: 94+/-14/61+/-8 mmHg; 200 mg: 99+/-15/62+/-9 mmHg; 400 mg: 106+/-16/58+/-9 mmHg; p<0.0001). Although the elevation in seated BP was relatively modest, average 4-hour seated SBP & DBP were significantly increased with 400 mg droxidopa compared to 100 mg (p<0.001) and 200 mg (p<0.05).

"These preliminary data indicate that droxidopa increases seated BP in a dose-dependent manner without worsening supine increases in BP in hypotensive persons with SCI, suggesting a greater normalization of pressure across positional changes," said lead author Jill M. Wecht, Ed.D, Associate Professor of Medicine and Rehabilitation Medicine, the Mount Sinai School of Medicine. "Increasing seated blood pressure is an important clinical outcome in these individuals, because hypotension has been linked to deficits in memory and attention processing in the general population and in individuals with SCI. Further study of droxidopa is warranted in the SCI population."

About Northera

NORTHERA(TM) (droxidopa), the lead investigational agent in Chelsea Therapeutics' pipeline, is currently in Phase III clinical trials for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) in patients with primary autonomic failure -- a group of diseases that includes Parkinson's disease, multiple system atrophy (MSA) and pure autonomic failure (PAF). Droxidopa is a synthetic catecholamine that is directly converted to norepinephrine (NE) via decarboxylation, resulting in increased levels of NE in the nervous system, both centrally and peripherally.

About Chelsea Therapeutics

Chelsea Therapeutics (CHTP) is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases, including central nervous system disorders. Chelsea is currently pursuing FDA approval in the U.S. for Northera(TM) (droxidopa), a novel, late-stage, orally-active therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure. For more information about the Company, visit http://www.chelseatherapeutics.com.

This press release contains forward-looking statements regarding future events. These statements are subject to risks and uncertainties that could cause the actual events or results to differ materially. These include the risk that the FDA will not accept any proposal regarding any trial or other data to support Study 301 or any other study, including the primary endpoint; the risk that we will not be able to resubmit the NDA for Northera and that the FDA will not approve a resubmitted NDA; the risk that our resources will not be sufficient to develop any study of Northera that will be acceptable to the FDA; the risk that we cannot complete any additional study for Northera without the need for additional capital; the risks and costs of drug development and that such development may take longer or be more expensive than anticipated; our need to raise additional operating capital in the future; our reliance on our lead drug candidate droxidopa; risk of regulatory approvals of droxidopa or our other drug candidates for additional indications; reliance on collaborations and licenses; intellectual property risks; our history of losses; competition; and market acceptance for our products if any are approved for marketing.

Originally posted here:
Chelsea Therapeutics Announces Results From Northera(TM) (droxidopa) Study in Spinal Cord Injury at the 23rd ...

Recommendation and review posted by sam

Assistive technologies a reassurance for spinal cord injuries

07 November 2012 This Spinal Cord Injury Awareness Week 6th-11th November is a national campaign that focuses on rebuilding the lives of people with devastating spinal cord injuries.

Assistive technology aims to aid people with newly acquired spinal injuries and people with existing conditions to maintain their independence in their own homes.

The Transitional Rehabilitation Program at the PA Hospital in Brisbane is one of the many users of Tunstall Healthcares assistive technology, providing independent solutions for its spinal patients.

In an emergency, Tunstalls personal alarm allows clients to make quick and easy contact with Tunstalls 24 hour response centre, where a response operator will speak to the client and organise the necessary assistance for them.

According to Telehealthcare Consultant Warren Duce personal alarms can be offered to provide additional support to patients being discharged from the unit.

Personal alarms are an added reassurance for discharged clients and their families, Mr Duce said.

The recovery period can be a difficult time for a spinal trauma patient, but with a personal alarm they know they can get help if they need it

Tunstall has available a variety of triggers including the sip/puff switch, head trigger wand and jelly bean button to help someone managing a spinal cord injury.

For people with unique limitations, Tunstall Healthcare can also create a customised radio trigger ensuring people with special and ongoing needs can maintain their independence.

Read more from the original source:
Assistive technologies a reassurance for spinal cord injury

Recommendation and review posted by sam

umbilical cord stem cells | Cord Blood Storage and Why
http://www.cordbloodrecommendation.com By preserving this cord blood through cord blood banking, your baby will be ensured a perfect source of cells in the event of some unfortunate accident, disease or other life threatening illness. Safety is a concern in the public banks because of the high cost of maintaining the storage unit. Besides this, children without siblings and people belonging to certain races or ethnicities, who don #39;t have access to other people of their race in their area, also face problems. Sources of stem cells, such as blood, fats, bone, or umbilical cords were simply named as sources, not as natural resources. By preserving your baby #39;s cord blood, you are actually saving your child from the dangers of waiting for matching donors during emergencies. ""Regenerative medicine is the next evolution of medical treatments. Stromal cells are a kind of cells that form bone, cartilage, fat, and fibrous connective tissue. There are people who are against this practice as well and there are many opinions supporting it too therefore it is best to consult your doctor regarding this issue and get the right advice. For this, the patient needs a donor whose tissues and cells match his own. In case the cord blood is collected before the removal of placenta, the umbilical cord is clamped and detached as usual. - Stem groups can be certainly obtained from cord blood- flex blood stem groups are a 100% reach for the patron, 50% reach for biological parents and 25% reach for blood ...From:Alexander santafeViews:0 0ratingsTime:01:13More inScience Technology

Continued here:
umbilical cord stem cells | Cord Blood Storage and Why - Video

Recommendation and review posted by sam

Biodegradable Systems In Tissue Engineering And Regenerative Medicine
ll4.me Biodegradable Systems In Tissue Engineering And Regenerative Medicine The most important materials in development for use in tissue engineering, replacement, and regeneration are based on polymers and on composites reinforced with bioactive ceramics. The first book to address the topic in an integrated manner, Biodegradable Materials in Tissue Engineering presents an extensive description of biodegradable polymers used in medicine and explores their design, development, and processing. The authors discuss the performance of biodegradable systems and the special requirements that should be taken into account when evaluating their biocompatibility. Included are several methodologies for tailoring cell adhesion and proliferation on the surface of biodegradable polymers. Publisher: CRC Press Illustration: N Language: ENG Title: Biodegradable Systems in Tissue Engineering and Regenerative Medicine Pages: 00000 (Encrypted PDF) On Sale: 2004-11-24 SKU-13/ISBN: 9780849319365 Category: Science : GeneralWords: in replacement The most important materials in development for use in tissue engineering, replacement, and regeneration are based on polymers and on composites reinforced with bioactive ceramics. The first book to a science, generalFrom:robertarellano9865Views:0 0ratingsTime:00:11More inPeople Blogs

Continue reading here:
Biodegradable Systems In Tissue Engineering And Regenerative Medicine - Video

Recommendation and review posted by sam

Pharma-Biotech Needs a New Financing Model or We Are Doomed!
Duane Roth, CEO, CONNECT Webinar Date: April 27, 2011 Agenda: What killed the fully integrated model? Has the start-up model run its course? What will the next model look like? Where will future investments come from? What role should federal and state government play? Speaker Biography: Duane J. Roth is Chief Executive Officer and Member of the Board of CONNECT. CONNECT is the globally recognized nonprofit organization dedicated to creating and sustaining the growth of innovative technology and life science businesses in San Diego. CONNECT has been directly involved with over 2000 companies since its inception in 1985 and these companies have secured over $10 billion in funding. Prior to joining CONNECT, Mr. Roth founded Alliance Pharmaceutical Corp., where he served as Chairman of the Board. Prior to Alliance, he held senior management positions at Johnson Johnson and Wyeth (now Pfizer) operating companies. He has served as a Member of the Board of Directors and executive committees of the Biotechnology Industry Organization (BIO), the California Healthcare Institute (CHI) and BIOCOM (past Chair). Mr. Roth was appointed to the oversight board of the California Institute of Regenerative Medicine (CIRM) by Governor Arnold Schwarzenegger in 2006 and was elected Vice Chairman in 2009.From:ShareVaultViews:0 0ratingsTime:53:57More inEducation

Read the original:
Pharma-Biotech Needs a New Financing Model or We Are Doomed! - Video

Recommendation and review posted by sam

ALACHUA, Fla.--(BUSINESS WIRE)--

AxoGen, Inc. (AXGN), a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions, today announced revenues for the third quarter ended September 30, 2012 of $1.98 million, a 74% increase over revenues of $1.14 million in the third quarter 2011.

Compared to last year, we delivered solid top-line growth during the quarter despite cash constraints and the distraction of raising capital, commented Karen Zaderej, Chief Executive Officer of AxoGen. In addition, to remain in compliance with covenants imposed by our former lender, we carefully managed cash and chose to defer certain sales force growth and marketing activities.

Ms. Zaderej continued, As a result of the recent financing with PDL, we paid off all bank debt and eliminated the restrictive lender requirements. This will allow us the flexibility to develop and expand our sales force and invest in significant marketing efforts.

Revenues

Revenues for the period were $1.98 million, a 74% increase, compared to $1.14 million for the same period in 2011. These results were due to expansion of sales and marketing efforts versus third quarter 2011 and focused on the development of new accounts as well as penetration into key accounts.

Revenues decreased 1.5% compared to second quarter 2012 revenues of $2.01 million. This is the second year in which the third quarter has been relatively flat compared to the second quarter. While this may suggest seasonality in peripheral nerve surgery, it is important to note that in both of these quarters there were material corporate transactions that may have distracted operations. In addition, during the period, the Company made personnel changes in certain sales territories, but did not increase the size of its direct sales force.

Gross Profit

Gross profit for the period increased to $1.44 million from the reported third quarter 2011 results of $10,000. The favorable results reflect increased revenues and lower manufacturing cost in 2012 and exclude an inventory write-off of $0.83, which occurred during the third quarter 2011.

The gross profit margin for the period increased to 73% compared to 0.9% for the same quarter last year.

Read more:
AxoGen, Inc. Announces Third Quarter 2012 Financial Results

Recommendation and review posted by sam

WINSTON-SALEM, N.C., Nov. 6, 2012 /PRNewswire/ --Tengion, Inc. (TNGN), a leader in regenerative medicine, today announced it will host a conference call and live audio webcast on Tuesday, November 13, 2012, at 8:30 a.m. EST to provide a business update and discuss its third quarter 2012 financial results.

To participate in the call, please dial 866-800-8651 (domestic) or 617-614-2704 (international) and reference access code 64284960.

The conference call can be accessed from the Investors section of the Company's website at http://www.tengion.com or directly at http://www.media-server.com/m/p/6pr35s84. The webcast will also be archived on the website.

About TengionTengion, a clinical-stage regenerative medicine company, is focused on developing its Organ Regeneration Platform to harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues with the goal of delaying or eliminating the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. An initial clinical trial is ongoing for the Company's most advanced product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like urinary tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company's lead preclinical candidate is the Neo-Kidney Augment, which is designed to prevent or delay dialysis kidney transplantation by increasing renal function in patients with advanced chronic kidney disease. Tengion has worldwide rights to its product candidates.

Originally posted here:
Tengion to Host Conference Call to Provide a Business Update and Report Third Quarter 2012 Financial Results on ...

Recommendation and review posted by sam

WINSTON-SALEM, N.C., Nov. 7, 2012 /PRNewswire/ --Tengion, Inc. (TNGN), a leader in regenerative medicine, today announced that John Miclot, President and Chief Executive Officer of Tengion, will present at the upcoming Lazard Capital Markets 9th Annual Healthcare Conference on Wednesday, November 14, 2012, at 11:30 a.m. EST in New York City.

A live audio webcast of the presentation can be accessed at http://www.wsw.com/webcast/lz13/tngn or under "Calendar of Events" in the Investors section of the Company's website at http://www.tengion.com. A replay of the presentation will be available on Tengion's website for 90 days. Investors interested in listening to the live webcast should log on before the start time in order to download any software required.

About Tengion

Tengion, a clinical-stage regenerative medicine company, is focused on developing its Organ Regeneration Platform to harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues with the goal of delaying or eliminating the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. An initial clinical trial is ongoing for the Company's most advanced product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like urinary tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company's lead preclinical candidate is the Neo-Kidney Augment, which is designed to prevent or delay dialysis kidney transplantation by increasing renal function in patients with advanced chronic kidney disease. Tengion has worldwide rights to its product candidates.

Visit link:
Tengion to Present at the Lazard Capital Markets 9th Annual Healthcare Conference

Recommendation and review posted by sam

Gov. Rick Perry today highlighted Texas leading role in the advancement of regenerative medicine to produce safe, effective and ethical adult stem cell therapies. The governor spoke at the inaugural Houston Stem Cell Summit, which focuses on adult stem cell research and its potential to tackle life-threatening diseases.

Im proud Texas is playing a key role in the advancement of adult stem cell research and therapies, both of which are promising for patients and our economy, Gov. Perry said. This conference represents another step in the growth of this industry that I hope and expect will be centered right here in the Lone Star State.

Texas has taken clear steps to advance research in ethical regenerative medicine as quickly and safely as possible, while protecting patients receiving these treatments in the state. Earlier this year, the Texas Legislature, Texas Medical Board and Texas Department of Health and Human Services set up a regulatory framework to guide companies, institutions and physicians collaborating to produce effective stem cell research.

Additionally, Texas continues to attract top researchers in biotechnology and regenerative medicine thanks to our commitment to investing in the technologies of the future through the Cancer Prevention Research Institute of Texas (CPRIT) and Texas Emerging Technology Fund (TETF). CPRIT has funded 427 awards totaling more than $756 million for cancer research, commercialization and prevention in academic institutions, non-profit organizations and private companies. The TETF has invested more than $180 million in grant-matching and research superiority funds in Texas universities, and more than $194 million in 137 early-stage companies, with more than $103 million of that going directly to biotechnology and life science companies.

Texas researchers have also received more than $52 million in National Institute of Health (NIH) funding in 2009 for adult stem cell studies. These grants have resulted in the Austin Heart Hospital successfully treating heart attack patients with adult stem cells, and success in treating spinal cord injuries and a variety of heart conditions.

The Houston Stem Cell Summit highlights the latest research and breakthroughs regarding the use of adult stem and progenitor cell therapies. The summit covers all aspects of emerging stem cell therapies including the latest in peer reviewed academic stem cell research, breakthroughs in adult stem cell therapies, patient experiences, the business of stem cell therapies and the evolving regulatory environment for stem cell therapies. For more information, please visit http://www.stemcellsummit.com/houston/. To view the governors full remarks, please visit http://governor.state.tx.us/news/speech/17803/

Original post:
Texas Can Become Center for Regenerative Medicine

Recommendation and review posted by sam

cord blood center | Cord Blood Transplantation - A Life Savior Technique
http://www.cordbloodrecommendation.com Storing your babies blood is painless, and causes no harm or pain to the child or mother. Anything that can help cure illnesses and several genetic diseases is worth at least researching and contemplating because you really do never know when you may need it. This type of stem cells is found in baby cord blood and adult bone marrow. Umbilical blood banking provides the ideal stem cell match should a patient require stem cell therapy in their lifetime. Hence opt for cord blood storage banks that can show proof of successful transplants from the cord blood units they have stored in order to avoid rude shocks. If you are an expecting mother, you can look for a bank or designated donation hospital in your community. In cases of leukemia, stem cells can be used to generate healthy blood and fight off the cancer cells in the body. Furthermore, collecting umbilical cord blood has no controversy since the process does not cause the destruction on the embryos and fetus. ""Leukemia is a type of cancer that begins from those tissues in the body that form blood. Ultra-modern cord blood banking technologies induce multiplication of cord blood stem cells by ex vivo expansion. Last but not the least, if you do not want to store the blood for your personal usage in any of these banks you can also donate it to the Medical Institutes for research purposes. Stem cells, researchers discovered, could cure many diseases such as leukemia and help others such as ...From:Implantes DentalesViews:1 0ratingsTime:01:31More inTravel Events

Original post:
cord blood center | Cord Blood Transplantation - A Life Savior Technique - Video

Recommendation and review posted by Bethany Smith

stem cells | Cryo-Cell - Cord Blood Banking Information For Parents
http://www.cordbloodrecommendation.com You never know when you might need this blood and it might give your child a new life. Why Bank Cord Blood?Cell therapy has become a more ideal method to treat certain diseases than bone morrow transplants. Most of the private and public banks were founded during the 1990s. In a laboratory test, cord blood stem cells were transplanted into rodents with controlled strokes. With the success from transfusions creating immune system stability, and creating new oxygen baring cells for many diseases, researchers are hoping that more diseases can not only be treated effectively, but possibly stopped in their tracks altogether. In cancer patients, such as those with leukemia, the introduction of HSC #39;s into the body may rapidly produce healthy cells that can replace destroyed cells from chemotherapy and/or hopefully prevent infections that often create complications or even death, during the treatment process. If you pass all the tests you will be free to donate your baby #39;s blood. Although some will allow you to prepay during your pregnancy so as to not have to pay the amount all in one lump sum, but in general all initial fees must be paid well in advance of delivery in order to utilize the private storage services. According to the most current data, the prospect of needing a stem cell transplant in any individuals Life is 1 in 217! So you can imagine that the likelihood of your baby, or one of your family members needing this kind of help is ...From:kristinagraddyViews:1 0ratingsTime:01:31More inTravel Events

Read the rest here:
stem cells | Cryo-Cell - Cord Blood Banking Information For Parents - Video

Recommendation and review posted by Bethany Smith

blood banks | Cryo-Cell - Cord Blood Banking Information For Parents
http://www.cordbloodrecommendation.com One main reason behind the importance of saving your newborn #39;s blood is that its use is mostly geared to close relatives within your direct bloodline. Why Bank Cord Blood?Cell therapy has become a more ideal method to treat certain diseases than bone morrow transplants. Human umbilical cord blood cells are rich in mescenchymal progenitor cells and contain a large number of endothelial cell precursors. I know this all sounds very technical and expensive. Relatives or other close friends who haven #39;t gone through cord blood banking may also benefit from the stem cells that can be derived from cord blood banking if and only if they will pose a close match with the cord blood banking donor #39;s stem cells. How is it stored?At the time of the baby #39;s birth, the doctor or nurse takes the cord blood and cryogenically freezes it. 4. As for other applications, though promising, they are still in the research stage. Stem cells are early cells that are capable of developing into red and white blood cells, and platelets. Numerous study reports reveal that more than 50 per cent of the potential donors are not eligible to donate cord blood. There is no clear proof to validate that stem cells of a relative are more successful than those taken from a stranger. So, day-by-day man is trying to reach the ultimate knowledge. Even if a lot of people think that extracting stem cells from human embryos is unethical, those stem cells can also be extracted from ...From:LosHotelesEnBogotaViews:2 0ratingsTime:01:31More inTravel Events

Here is the original post:
blood banks | Cryo-Cell - Cord Blood Banking Information For Parents - Video

Recommendation and review posted by Bethany Smith

FAQ-10 of 19: Can Stem Cells Cause Cancer From Stem Cell Therapy?
youtu.be People ask us if stem cell therapy can CAUSE cancer, and they are wise to be wary, but stem cell therapy has been proving effective AGAINST cancer, and has not cause any known cases of cancer to-date. For more personalized information, visit StemCell-Asia.info now.From:Karridine1Views:1 0ratingsTime:01:06More inPeople Blogs

Link:
FAQ-10 of 19: Can Stem Cells Cause Cancer From Stem Cell Therapy? - Video

Recommendation and review posted by Bethany Smith

FAQ-11 of 19: For Stem Cell Therapy, Why Thailand #39;s Licensed Stem Cell Treatments?
youtu.be You may wonder why coming to Thailand is a better investment of time, energy and resources, so here are some answers. For more personalized information as to how your condition might respond to stem cell therapy, go to the Apply Now page and send in copies of your medical records with an Application for Consideration. StemCell-Asia.infoFrom:Karridine1Views:1 0ratingsTime:01:16More inPeople Blogs

Visit link:
FAQ-11 of 19: For Stem Cell Therapy, Why Thailand's Licensed Stem Cell Treatments? - Video

Recommendation and review posted by Bethany Smith